Standalone & Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Titan Securities reported mixed FY2026 results. Standalone revenue declined significantly to Rs. 596.32 lakh from Rs. 1,045.84 lakh in FY2025, a drop of about 43%. However, consolidated PAT grew 19% to Rs. 1,245.57 lakh (vs Rs. 1,047.36 lakh), driven by strong share in associate profits of Rs. 1,162.02 lakh from Titan Biotech and Peptech Biosciences. The CFO, Mrs. Darshana Santoshi, resigned effective May 30, 2026 citing personal reasons. Auditors Goyal Nagpal & Co issued unmodified opinions on both standalone and consolidated results. The company also changed measurement basis for its Peptech Biosciences investment from FVOCI to cost due to strategic intent change.
Revenue decline is a concern for standalone performance, but strong associate contributions and consolidated PAT growth may support the stock. CFO resignation adds near-term uncertainty about financial management continuity.